Company intelligence / Profile preview
BioTheraVision
Chicago, Illinois, United Statesbiotheravision.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioTheraVision is a privately held, pre-clinical to early clinical stage pharmaceutical company focused on developing ophthalmic therapeutics. Its lead asset is cevimeline hydrochloride, a small molecule targeting the M1 and M3 muscarinic acetylcholine receptors for the treatment of dry eye syndromes. The program has reached Phase 2 clinical development as of May 2025. No published clinical results are available in public sources as of June 2025.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on BioTheraVision.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioTheraVision.